T cell-based immunotherapies have begun to transform how we treat cancer, but are only sometimes effective and can cause serious adverse events. My research group combines mechanistic immunology and protein engineering with the goal of engineering the immune system. We develop approaches to create safer, more effective cancer immunotherapies.
Fellow
